UNSPSC 51292805: Doxepin hydrochloride

This classification denotes a tricyclic antidepressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U9A0FE9N5. European Medicines Agency schedules Doxepin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01825MIG. Doxepin hydrochloride generally arises in the molecular formula C19H21NO.CLH. The term 'doxepin hydrochloride' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule doxepin hydrochloride under HS 29329985 and SITC 51569.

Doxepin hydrochloride bears US NLM identifiers UMLS ID C0700535 and NCI Concept Code C29006. SMILES: As of Q4 2014, DOXEPIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

UNSPSC 51292805 Doxepin hydrochloride is a Commodity code that covers specific pharmaceutical products state and local governments purchase through health agencies, county health departments, and cooperative purchasing alliances. Recent opportunities show state and local buyers procuring prescription medications and OTC products primarily through competitive bidding and cooperative purchasing vehicles rather than as standalone commodity acquisitions. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering agreements across participating states including Oregon). These jurisdictions source generic pharmaceuticals and specialized health products through established wholesaler networks and direct-to-manufacturer programs to support community health initiatives, employee health plans, and institutional pharmacy operations.

Recent activity shows geographic concentration in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the response deadline was July 26, 2023. Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program supporting direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (S1070000015802) on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson); proposals were due March 26, 2026, with awards effective July 1, 2026. The MMCAP solicitation weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of the three authorized wholesalers and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act.